NHPN-1010: Phase I started

In November, Otologic said it began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single doses of 500, 1,000 and 1,500 mg oral HPN-07 alone and HPN-07 at the maximum tolerated dos...